GeoVax Labs reported Q2 2024 financial results, with revenue of $300,677 from a BARDA contract for its COVID-19 vaccine GEO-CM04S1. Net loss narrowed to $5.06M from $5.93M YoY. R&D expenses decreased 9.4% to $4.28M, while G&A expenses fell 25.6% to $1.09M.The company was awarded a $24.3M BARDA contract to advance GEO-CM04S1 through a 10,000-participant Phase 2b trial. GEO-CM04S1 is also in Phase 2 trials as a vaccine for immunocompromised patients and as a heterologous booster. Gedeptin, GeoVax's gene therapy for head and neck cancer, is advancing to an expanded Phase 2 trial.As of June 30, GeoVax had $1.56M in cash, down from $6.45M at 2023 year-end. The company raised $2.8M in July 2024 but still faces liquidity concerns, stating current funds are insufficient beyond Q3 2024 without additional financing. Management is actively pursuing funding options to continue operations and advance clinical programs.

GeoVax Labs reported Q2 2024 financial results, with revenue of $300,677 from a BARDA contract for its COVID-19 vaccine GEO-CM04S1. Net loss narrowed to $5.06M from $5.93M YoY. R&D expenses decreased 9.4% to $4.28M, while G&A expenses fell 25.6% to $1.09M.The company was awarded a $24.3M BARDA contract to advance GEO-CM04S1 through a 10,000-participant Phase 2b trial. GEO-CM04S1 is also in Phase 2 trials as a vaccine for immunocompromised patients and as a heterologous booster. Gedeptin, GeoVax's gene therapy for head and neck cancer, is advancing to an expanded Phase 2 trial.As of June 30, GeoVax had $1.56M in cash, down from $6.45M at 2023 year-end. The company raised $2.8M in July 2024 but still faces liquidity concerns, stating current funds are insufficient beyond Q3 2024 without additional financing. Management is actively pursuing funding options to continue operations and advance clinical programs.